RegeneRx

Overview

Our Mission

To develop and commercialize novel pharmaceutical products that prevent or repair tissue and organ damage caused by disease, trauma, or other pathology. More>>

Stock Quote
RGN (Common Stock)
ExchangeAMEX (US Dollar)
Price$1.11
Change (%) Stock is Down 0.09 (7.50%)
Volume14,200
Data as of 11/20/08 3:59 p.m. ET
Minimum 20 minute delay
Refresh quote
Featured Report
There are currently no items available.
Recent NewsMore >>
DateTitle 
11/18/08[video] Wall St. Network's 3-Minute Press Show Features Executive Interviews and Highlights Recent Press for the Following: RGN, IXS, DLKM, VCRT, GTLTPrinter Friendly Version
11/17/08RegeneRx's Experimental Drug Promotes Healing in Patients With Non-Healing Corneal UlcersPrinter Friendly Version
11/04/08RegeneRx President and CEO to Speak at Rodman & Renshaw Annual Global Investment ConferencePrinter Friendly Version
10/24/08RegeneRx Sponsors "Walk a Mile in My Shoes" for National Epidermolysis Bullosa Awareness WeekPrinter Friendly Version
Contact Information
Primary IR Contact
C. Neil Lyons
Chief Financial Officer
RegeneRx Biopharmaceuticals, Inc.
3 Bethesda Metro Center
Suite 630
Bethesda, MD 20814
Phone: 301-280-1992
Fax: 301-280-1996
E-mail: info@regenerx.com

Transfer Agent
American Stock Transfer
6201 15 Avenue
Brooklyn, NY 11129
Phone: 718-921-8335


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

     
home|Contact Us|Resources|Site Map|
Search